Optimizing detection of Alzheimer’s disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO

Abstract Background Disease-modifying drug use necessitates better Alzheimer disease (AD) detection. Mild cognitive impairment (MCI) leverages cognitive decline to identify the risk group; similarly, mild behavioral impairment (MBI) leverages behavioral change. Adding MBI to MCI improves dementia pr...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Zahinoor Ismail, Rebeca Leon, Byron Creese, Clive Ballard, Philippe Robert, Eric E. Smith
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	BMC 2023-07-01
Rangatū:	Molecular Neurodegeneration
Ngā marau:	Alzheimer’s disease Mild cognitive impairment Prodromal disease Neuropsychiatric symptoms Mild behavioral impairment Biomarkers
Urunga tuihono:	https://doi.org/10.1186/s13024-023-00631-6
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!